Table 3 Targeted drug used in each group with respective sample size and duration
Trial | Targeted Drug | Target sample size | Duration/ month | |
|---|---|---|---|---|
ARISTOTLE* | Intervention | Apixaban 5 mg BD | 2438 | 21.8 |
(Avezum et al., 2015) | Control | Wafarin (INR 2–3) | 2370 | |
ENGAGE AF-TIMI 48* | Intervention | Edoxaban 60 mg QD | 1869 | 33.6 |
(De Caterina et al., 2017) | Control | Warfarin (INR 2–3) | 955 | |
RE-LY | Intervention | Pradaxa 110/150 mg QD | 2646 | 36 |
(Ezekowitz et al., 2016) | Control | Warfarin (INR 2–3) | 652 | |
ROCKET AF* | Intervention | Rivaroxaban 20 mg QD | 939 | 48 |
(Breithardt et al., 2016) | Control | Warfarin (INR 2–3) | 1001 | |
Seeger et al. | Intervention | Apixaban | 141 | 1, 12 |
−2017 | Control | Phenprocoumon | 131 | |
Geis et al. | Intervention | NOAC | 154 | 6 |
−2018 | Control | Warfarin (INR 2–3) | 172 | |